Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrey Ugolkov

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Cell Cycle (Georgetown, Tex.)|January 7, 2012
Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modalityAlexander Yemelyanov, Pankaj Bhalla, Ximing Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2010
Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancerSei Naito, Vladimir Bilim, Kaori Yuuki, et al.
Oncology Reports|September 1, 2021
Development of patient‑derived tumor organoids and a drug testing model for renal cell carcinomaAkira Kazama, Tsutomu Anraku, Hiroo Kuroki, et al.
Cancer Letters|November 19, 2011
Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3βMasaaki Tsukigi, Vladimir Bilim, Kaori Yuuki, et al.
Oncotarget|February 1, 2018
GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agentsReem Karmali, Vineela Chukkapalli, Leo I Gordon, et al.
ACS Nano|August 30, 2012
Coassembled cytotoxic and pegylated peptide amphiphiles form filamentous nanostructures with potent antitumor activity in models of breast cancerDaniel J Toft, Tyson J Moyer, Stephany M Standley, et al.
Cancer Research|February 28, 2016
Melanoma Cells Block PEDF Production in Fibroblasts to Induce the Tumor-Promoting Phenotype of Cancer-Associated FibroblastsNkechiyere G Nwani, Maria L Deguiz, Benilde Jimenez, et al.
International Journal of Molecular Medicine|January 3, 2020
Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancerTsutomu Anraku, Hiroo Kuroki, Akira Kazama, et al.
Scientific Reports|December 29, 2019
9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancerHiroo Kuroki, Tsutomu Anraku, Akira Kazama, et al.
Neoplasia (New York, N.Y.)|October 18, 2015
Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic TumorsGennadiy Bondarenko, Andrey Ugolkov, Stephen Rohan, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Cell Cycle (Georgetown, Tex.)|January 7, 2012
Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modalityAlexander Yemelyanov, Pankaj Bhalla, Ximing Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2010
Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancerSei Naito, Vladimir Bilim, Kaori Yuuki, et al.
Oncology Reports|September 1, 2021
Development of patient‑derived tumor organoids and a drug testing model for renal cell carcinomaAkira Kazama, Tsutomu Anraku, Hiroo Kuroki, et al.
Cancer Letters|November 19, 2011
Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3βMasaaki Tsukigi, Vladimir Bilim, Kaori Yuuki, et al.
Oncotarget|February 1, 2018
GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agentsReem Karmali, Vineela Chukkapalli, Leo I Gordon, et al.
ACS Nano|August 30, 2012
Coassembled cytotoxic and pegylated peptide amphiphiles form filamentous nanostructures with potent antitumor activity in models of breast cancerDaniel J Toft, Tyson J Moyer, Stephany M Standley, et al.
Cancer Research|February 28, 2016
Melanoma Cells Block PEDF Production in Fibroblasts to Induce the Tumor-Promoting Phenotype of Cancer-Associated FibroblastsNkechiyere G Nwani, Maria L Deguiz, Benilde Jimenez, et al.
International Journal of Molecular Medicine|January 3, 2020
Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancerTsutomu Anraku, Hiroo Kuroki, Akira Kazama, et al.
Scientific Reports|December 29, 2019
9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancerHiroo Kuroki, Tsutomu Anraku, Akira Kazama, et al.
Neoplasia (New York, N.Y.)|October 18, 2015
Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic TumorsGennadiy Bondarenko, Andrey Ugolkov, Stephen Rohan, et al.
Pageof 3